112 related articles for article (PubMed ID: 38716219)
1. Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379).
Almhanna K; Breakstone R; Raufi A; Wood R; Webber A; Dionson S; Cavanagh L; Seyhan AA; Safran H; El-Deiry W
Transl Gastroenterol Hepatol; 2024; 9():15. PubMed ID: 38716219
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Fukuoka S; Hara H; Takahashi N; Kojima T; Kawazoe A; Asayama M; Yoshii T; Kotani D; Tamura H; Mikamoto Y; Hirano N; Wakabayashi M; Nomura S; Sato A; Kuwata T; Togashi Y; Nishikawa H; Shitara K
J Clin Oncol; 2020 Jun; 38(18):2053-2061. PubMed ID: 32343640
[TBL] [Abstract][Full Text] [Related]
3. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.
Kim RD; Kovari BP; Martinez M; Xie H; Sahin IH; Mehta R; Strosberg J; Imanirad I; Ghayouri M; Kim YC; Kim DW
Eur J Cancer; 2022 Jul; 169():93-102. PubMed ID: 35526308
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
Fakih M; Sandhu J; Lim D; Li X; Li S; Wang C
JAMA Oncol; 2023 May; 9(5):627-634. PubMed ID: 36892833
[TBL] [Abstract][Full Text] [Related]
5. CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial.
Saunders MP; Graham J; Cunningham D; Plummer R; Church D; Kerr R; Cook S; Zheng S; La Thangue N; Kerr D
ESMO Open; 2022 Dec; 7(6):100594. PubMed ID: 36327756
[TBL] [Abstract][Full Text] [Related]
6. TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
Kawazoe A; Itahashi K; Yamamoto N; Kotani D; Kuboki Y; Taniguchi H; Harano K; Naito Y; Suzuki M; Fukutani M; Higuchi T; Ikeno T; Wakabayashi M; Sato A; Koyama S; Nishikawa H; Shitara K
Clin Cancer Res; 2021 Dec; 27(24):6709-6715. PubMed ID: 34593531
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36634920
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
[TBL] [Abstract][Full Text] [Related]
9. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
[TBL] [Abstract][Full Text] [Related]
10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
11. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
Stein MN; Malhotra J; Tarapore RS; Malhotra U; Silk AW; Chan N; Rodriguez L; Aisner J; Aiken RD; Mayer T; Haffty BG; Newman JH; Aspromonte SM; Bommareddy PK; Estupinian R; Chesson CB; Sadimin ET; Li S; Medina DJ; Saunders T; Frankel M; Kareddula A; Damare S; Wesolowsky E; Gabel C; El-Deiry WS; Prabhu VV; Allen JE; Stogniew M; Oster W; Bertino JR; Libutti SK; Mehnert JM; Zloza A
J Immunother Cancer; 2019 May; 7(1):136. PubMed ID: 31118108
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer.
Akce M; Farran B; Switchenko JM; Rupji M; Kang S; Khalil L; Ruggieri-Joyce A; Olson B; Shaib WL; Wu C; Alese OB; Diab M; Lesinski GB; El-Rayes BF
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852737
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.
Fakih M; Raghav KPS; Chang DZ; Larson T; Cohn AL; Huyck TK; Cosgrove D; Fiorillo JA; Tam R; D'Adamo D; Sharma N; Brennan BJ; Wang YA; Coppieters S; Zebger-Gong H; Weispfenning A; Seidel H; Ploeger BA; Mueller U; Oliveira CSV; Paulson AS
EClinicalMedicine; 2023 Apr; 58():101917. PubMed ID: 37090438
[TBL] [Abstract][Full Text] [Related]
14. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
[TBL] [Abstract][Full Text] [Related]
15. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
[TBL] [Abstract][Full Text] [Related]
17. Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
Awad MM; Le Bruchec Y; Lu B; Ye J; Miller J; Lizotte PH; Cavanaugh ME; Rode AJ; Dumitru CD; Spira A
Front Oncol; 2021; 11():696512. PubMed ID: 34552864
[TBL] [Abstract][Full Text] [Related]
18. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
Coffman-D'Annibale K; Myojin Y; Monge C; Xie C; Hrones DM; Wood BJ; Levy EB; Kleiner D; Figg WD; Steinberg SM; Redd B; Greten TF
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38184304
[TBL] [Abstract][Full Text] [Related]
19. A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
Silk AW; Saraiya B; Groisberg R; Chan N; Spencer K; Girda E; Shih W; Palmeri M; Saunders T; Berman RM; Coric V; Chen S; Zloza A; Vieth J; Mehnert JM; Malhotra J
Eur J Med Res; 2022 Jul; 27(1):107. PubMed ID: 35780243
[TBL] [Abstract][Full Text] [Related]
20. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
